News & Updates
Filter by Specialty:
Show Multimedia Only
OLE data FORTIFY risankizumab role in Crohn’s disease
13 Dec 2024
byAudrey Abella
Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
OLE data FORTIFY risankizumab role in Crohn’s disease
13 Dec 2024
Methylnaltrexone no better than placebo in easing acute pancreatitis severity
12 Dec 2024
Treatment with methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, does not significantly reduce the severity of acute pancreatitis (AP) relative to placebo, a study has shown.
Methylnaltrexone no better than placebo in easing acute pancreatitis severity
12 Dec 2024
Pooled analysis ASSUREs seladelpar role in PBC
04 Dec 2024
byAudrey Abella
Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).